Comprehensive Financial Planning Inc. PA Purchases Shares of 28,106 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Comprehensive Financial Planning Inc. PA acquired a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 28,106 shares of the company’s stock, valued at approximately $190,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in RXRX. Stratos Wealth Partners LTD. acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth $112,000. China Universal Asset Management Co. Ltd. lifted its holdings in Recursion Pharmaceuticals by 53.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 80,943 shares of the company’s stock worth $547,000 after purchasing an additional 28,038 shares during the period. Clear Creek Financial Management LLC grew its position in Recursion Pharmaceuticals by 57.6% in the 4th quarter. Clear Creek Financial Management LLC now owns 19,408 shares of the company’s stock valued at $131,000 after buying an additional 7,095 shares in the last quarter. Institute for Wealth Management LLC. acquired a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $3,928,000. Finally, Cherry Creek Investment Advisors Inc. raised its position in shares of Recursion Pharmaceuticals by 8.3% during the 4th quarter. Cherry Creek Investment Advisors Inc. now owns 62,127 shares of the company’s stock worth $420,000 after buying an additional 4,787 shares in the last quarter. 89.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on RXRX. KeyCorp lowered their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday.

Recursion Pharmaceuticals Stock Up 3.5 %

NASDAQ RXRX opened at $7.49 on Monday. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.60 and a 12 month high of $15.74. The company’s 50 day simple moving average is $7.15 and its 200 day simple moving average is $6.89. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Insiders Place Their Bets

In related news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at $11,487,173.46. The trade was a 0.99 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total value of $87,455.08. Following the sale, the director now directly owns 7,066,113 shares of the company’s stock, valued at approximately $53,985,103.32. This represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 15.75% of the stock is currently owned by company insiders.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.